Fabian Gerlinghaus
CEO and Co-Founder, Cellares
In his role with Cellares, Fabian focuses on automated manufacturing platforms. In 2024, he oversaw the launch of the Cell Shuttle, attracting partnerships with industry leaders Bristol Myers Squibb and Kite, a Gilead Company, to automate CAR-T cell therapy manufacturing – as well as rubbing shoulders with CAR-T cell therapy pioneer Carl June. A regular Power Lister since 2021, Fabian is passionate about setting new standards for accessibility, efficiency, and reliability in cell therapy manufacturing.
“A few decades from now, we will eradicate cancer entirely. Patients will be diagnosed by AI; we will sequence the tumors and produce an individualized treatment of CAR-T cells, armed against neoantigens found specifically on that patient's tumor, alongside individualized mRNA therapeutics that target the neoantigens found in the outpatient's tumor. In other words, we'll have a generalized approach to eliminating cancer.”
